317 related articles for article (PubMed ID: 14595340)
1. Concerns raised over declining antiinfectives R&D.
Fox JL
Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
[No Abstract] [Full Text] [Related]
2. A changing drug supply.
Nature; 2007 Feb; 445(7127):460. PubMed ID: 17268432
[No Abstract] [Full Text] [Related]
3. What does R&D really cost?
Huff B
GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
[No Abstract] [Full Text] [Related]
4. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
Matheny J; Smith B; Courtney B; Mair M
Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
[No Abstract] [Full Text] [Related]
5. Key factors in the rising cost of new drug discovery and development.
Dickson M; Gagnon JP
Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
[No Abstract] [Full Text] [Related]
6. Clinical research: outlook from industry.
Echols R
Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
[No Abstract] [Full Text] [Related]
7. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim AS
Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
[No Abstract] [Full Text] [Related]
8. Trends in antimicrobial drug development: implications for the future.
Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
[TBL] [Abstract][Full Text] [Related]
9. A merger too far?
Wadman M
Nature; 2007 Mar; 446(7131):15. PubMed ID: 17330017
[No Abstract] [Full Text] [Related]
10. Therapeutic breakthroughs in the millennium: what to look for in the next two decades. Part 2: New therapeutics reverse old thinking.
Davidson S
Health Forum J; 1999; 42(2):61-3. PubMed ID: 10538905
[No Abstract] [Full Text] [Related]
11. Pharmaceutical manufacturers ... leaving tradition behind and forging new managed care alliances.
Barnett AA
State Health Care Am; 1995; ():41-6. PubMed ID: 10168072
[No Abstract] [Full Text] [Related]
12. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
13. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
14. Pipelines turn to biotech.
Lawrence S
Nat Biotechnol; 2007 Dec; 25(12):1342. PubMed ID: 18066015
[No Abstract] [Full Text] [Related]
15. New drug approvals for 2002.
Frantz S; Smith A
Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538
[No Abstract] [Full Text] [Related]
16. Developing drugs for developing countries.
Ridley DB; Grabowski HG; Moe JL
Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
[TBL] [Abstract][Full Text] [Related]
17. Rising costs hold up drug discovery.
Miller HI
Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
[No Abstract] [Full Text] [Related]
18. Study reveals secrets to faster drug development.
Frantz S
Nat Rev Drug Discov; 2006 Nov; 5(11):883. PubMed ID: 17117519
[No Abstract] [Full Text] [Related]
19. An audience with...Marc Cluzel.
Cluzel M
Nat Rev Drug Discov; 2010 Jan; 9(1):14. PubMed ID: 20043024
[TBL] [Abstract][Full Text] [Related]
20. Swimming upstream: an advocate reflects on cancer research and social realities.
Mayer M
J Clin Oncol; 2008 Jun; 26(16):2783-6. PubMed ID: 18509190
[No Abstract] [Full Text] [Related]
[Next] [New Search]
